Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report

Guillemois, S.; Patsouris, Anne; Peyraga, G.; Chassain, K.; Corre, Y. Le; Campone, Mario; Augereau, Paule

doi:10.1016/j.clbc.2018.07.006

Cited by 9 publications

(33 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[181][182][183][184][185][186][187][188][189] There are rare reported cases (although more than with other Nibs) of blistering dermatitis (9%), including bullous pemphigoid. 190,191 Cases of discoid or subacute chronic lupus, [192][193][194][195] ashy dermatosis (erythema dyschromicum perstans), 196 leukocytoclastic vasculitis, 197 and SJS [198][199][200][201] have also been reported with CDK4/6 inhibitors. $20% to 80%-90%, making CML the first cancer to strongly respond to targeted anticancer therapy.…”

Section: Cdk4/6 Inhibitorsmentioning

confidence: 99%

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

et al. 2021

View full text Add to dashboard Cite

Background: Advances in molecular biology and genetics have contributed to breakthrough treatments directed at specific pathways associated with the development of cancer. Small-molecule inhibitors (Nibs) aimed at a variety of cellular pathways have been efficacious; however, they are associated with significant dermatologic toxicities. Methods: We conducted a comprehensive review of dermatologic toxicities associated with Nibs categorized into the following five groups: (a) mitogen-activated protein kinase; (b) growth factor/multi-tyrosine kinase; (c) cell division/DNA repair; (d) signaling associated with myeloproliferative neoplasms; and (e) other signaling pathways. Prospective phase I, II, or III clinical trials, retrospective literature reviews, systematic reviews/meta-analyses, and case reviews/reports were included for analysis.Results: Dermatologic toxicities reviewed were associated with every class of Nibs and ranged from mild to severe or life-threatening adverse skin reactions.Inflammatory reactions manifesting as maculopapular, papulopustular/acneiform, and eczematous lesions were frequent types of dermatologic toxicities seen with Nibs.Squamous cell carcinoma with keratoacanthoma-like features was associated with a subset of Nibs. Substantial overlap in dermatologic toxicities was found between Nibs.Conclusions: Dermatologic toxicities from Nibs are diverse and may overlap between classes of Nibs. Recognition of the various types of toxicities from Nibs is critical for patient care in the era of "oncodermatology/dermatopathology."

show abstract

Section: Cdk4/6 Inhibitorsmentioning

confidence: 99%

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Ibrance is the first CDK4/6 inhibitor 1 approved by FDA (the U.S. Food and Drug Administration) in 2015 to block the proliferation of tumor cells, and its combination with letrozole can effectively treat ER/HER2-postmenopausal advanced breast cancer. 2 6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido [2,3]pyrimidin-7(8H)one is a key drug intermediate for the synthesis of Ibrance mentioned in some articles. 1−4 We all know that recrystallization is one of the most important applications for improving the purity of substances in the pharmaceutical field.…”

Section: Introductionmentioning

confidence: 99%

“…1−4 We all know that recrystallization is one of the most important applications for improving the purity of substances in the pharmaceutical field. So far, the research studies on 6bromo-2-chloro-8-cyclopentyl-5-methylpyrido [2,3]pyrimidin-7(8H)-one have mostly focused on organic synthesis. 1−4 However, there is no research on the solubility of 6-bromo-2chloro-8-cyclopentyl-5-methylpyrido [2,3]pyrimidin-7(8H)one.…”

Section: Introductionmentioning

confidence: 99%

“…So far, the research studies on 6bromo-2-chloro-8-cyclopentyl-5-methylpyrido [2,3]pyrimidin-7(8H)-one have mostly focused on organic synthesis. 1−4 However, there is no research on the solubility of 6-bromo-2chloro-8-cyclopentyl-5-methylpyrido [2,3]pyrimidin-7(8H)one. Therefore, it is necessary to study the solubility of 6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido [2,3]pyrimidin-7(8H)-one in order to determine the appropriate solvents and the production process of 6-bromo-2-chloro-8-cyclopentyl-5methylpyrido [2,3]pyrimidin-7(8H)-one.…”

Section: Introductionmentioning

confidence: 99%

“…In this study, we used liquid chromatography to study the solubility of 6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido- [2,3]pyrimidin-7(8H)-one in 10 pure solvents [dichloromethane, n-hexane, ethyl acetate, n-butyl alcohol, tetrahydrofuran (THF), ethyl alcohol, isopropanol, 1-propanol, dimethylformamide (DMF), and isophorone] and 3 mixed solvents (ethyl acetate + ethyl alcohol, isophorone + isopropanol, and THF + ethyl alcohol) from 278. 15 2.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Solid–Liquid Equilibrium and Thermodynamic Properties of 6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3]pyrimidin-7(8H)-one in 10 Pure Solvents and 3 Different Miscible Systems at T = (278.15–323.15) K

Yang

et al. 2021

J. Chem. Eng. Data

View full text Add to dashboard Cite

6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3]pyrimidin-7(8H)-one is a key intermediate in the synthesis of Ibrance. We used high-performance liquid chromatography to analyze the solubility of 6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3]pyrimidin-7(8H)-one in 10 single solvents [dichloromethane, n-hexane, ethyl acetate, n-butyl alcohol, tetrahydrofuran (THF), ethyl alcohol, isopropanol, 1-propanol, dimethylformamide, and isophorone] and 3 binary solvents (ethyl acetate + ethyl alcohol, isophorone + isopropanol, and THF + ethyl alcohol) at atmospheric pressure from 278.15 to 323.15 K. The results show that temperature and the solubility of 6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3]pyrimidin-7(8H)-one in single solvents and binary solvents are positively correlated. The solubility in pure solvents is fitted by the modified Apelblat model and the Buchwski–Ksiazaczak λh model, and the solubility data in the binary solvent are correlated by the CNIBS/R–K model and the Jouyban–Acree model. The good agreement between the calculated value of the equation and the experimental result is shown by the results of equation fitting. By comparing the average value of relative average deviation and root-mean-square deviation of the equations, we can see that the modified Apelblat model has the best correlation effect in the single solution systems and the CNIBS/R–K model has the best correlation effect in the miscible systems. The KAT-LSER model is used to explain the competition between solute–solvent interactions and solvent–solvent interactions in pure solvents.

show abstract

Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report

Cited by 9 publications

References 16 publications

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

Solid–Liquid Equilibrium and Thermodynamic Properties of 6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3]pyrimidin-7(8H)-one in 10 Pure Solvents and 3 Different Miscible Systems at T = (278.15–323.15) K

Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review

Contact Info

Product

Resources

About